STA Signs Five-Year Supply Agreement with Tesaro
STA will provide supplies of certain starting and intermediate materials for Tesaro’s recently launched Zejula (niraparib), an orally active and potent poly(ADP-ribose) polymerase inhibitor approved by FDA for the treatment of ovarian cancer.
STA Pharmaceutical, a WuXi AppTec subsidiary, announced on July 24, 2017 that it has signed a supply agreement with oncology-focused biopharmaceutical company Tesaro for certain starting and intermediate materials for Zejula (niraparib).
Under the five-year agreement, STA will provide supplies of certain starting and intermediate materials for the recently launched Zejula. This agreement follows a successful multiple-year development and clinical manufacturing arrangement with Tesaro and STA’s assistance with the expedited new drug application submission and final approval by FDA.
Zejula is an orally active and potent poly(ADP-ribose) polymerase (PARP) inhibitor approved by FDA on March 27, 2017 for the treatment of epithelial ovarian, fallopian tube, and primary peritoneal cancer. It is now available to patients in the United States. It is the only PARP inhibitor that has demonstrated a clinically meaningful increase in progression-free survival (PFS) in women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status, in a randomized, prospectively designed Phase III clinical trial.
Source: WuXi AppTec
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
